Page last updated: 2024-11-03

probucol and Dyslipidemia

probucol has been researched along with Dyslipidemia in 4 studies

Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.

Research Excerpts

ExcerptRelevanceReference
"To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers."5.22Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Chung, CH; Han, KA; Hwang, YC; Jin, SM; Ko, SH; Lee, HW; Lee, IK; Lee, MK; Nam, MS; Park, IeB; Park, TS; Rhee, EJ; Sohn, TS; Yu, JM, 2016)
"Regarding patients with familial hypercholesterolemia, those treated with probucol, which is a potent anti-oxidative and anti-hyperlipidemic drug, showed significantly lower Ox-HDL (16."1.62Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein. ( Inui, H; Kanno, K; Katayama, Y; Koseki, M; Masuda, D; Nishida, M; Ohama, T; Okada, T; Saga, A; Sakata, Y; Sumida, M; Yamashita, S, 2021)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Okada, T1
Sumida, M1
Ohama, T1
Katayama, Y1
Saga, A1
Inui, H1
Kanno, K1
Masuda, D1
Koseki, M1
Nishida, M1
Sakata, Y1
Yamashita, S1
Hirata, KI1
Jin, SM1
Han, KA1
Yu, JM1
Sohn, TS1
Choi, SH1
Chung, CH1
Park, IeB1
Rhee, EJ1
Baik, SH1
Park, TS1
Lee, IK1
Ko, SH1
Hwang, YC1
Cha, BS1
Lee, HW1
Nam, MS1
Lee, MK1
Fukumoto, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.[NCT01726816]Phase 2126 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for probucol and Dyslipidemia

ArticleYear
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Arteriosclerosis, thrombosis, and vascular biology, 2016, Volume: 36, Issue:10

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2016

Other Studies

3 other studies available for probucol and Dyslipidemia

ArticleYear
Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
    Journal of atherosclerosis and thrombosis, 2021, Jul-01, Volume: 28, Issue:7

    Topics: Adult; Antioxidants; Atherosclerosis; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Huma

2021
New Evidence of Probucol on Cardiovascular Events.
    Journal of atherosclerosis and thrombosis, 2021, Feb-01, Volume: 28, Issue:2

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Dyslipidem

2021
[Medicines for dyslipidemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 6

    Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart F

2012